Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Herpes simplex virus 1 UL52 primase is the primase subunit of the heterotrimeric helicase-primase (HP) complex, alongside UL5 (helicase) and UL8 (auxiliary), essential for HSV-1 DNA replication. It synthesizes short RNA primers on single-stranded DNA templates at replication forks, enabling DNA polymerase to initiate leading and lagging strand synthesis, while exhibiting structural features like conserved catalytic motifs (I, II, III), a zinc-binding domain, and domains (NTD, MD, CTD) that scaffold complex assembly and DNA binding. UL52 binds ssDNA tails, coordinates with UL5 for 5'-3' translocation and duplex unwinding, and requires dimerization of the HP complex for full primase activity. In HSV-1 infection, it drives viral genome replication post-origin recognition by UL9 and ICP8, making the HP complex a validated antiviral target. Inhibitors like amenamevir and pritelivir bind the UL5-UL52 interface, blocking translocation and primer formation to halt replication. Cryo-EM structures reveal UL52's bilobed architecture stabilizing the complex, with mutations disrupting zinc binding or subunit interactions abolishing activity and viral propagation. Neither UL52 nor UL5 functions enzymatically alone, underscoring their interdependence.
Inhibition of helicase-primase complex activity, Disruption of viral DNA unwinding and primer synthesis
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Herpes simplex virus 1 UL52 primase (UL52).